| Not Yet Recruiting | Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC NCT07392073 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | PALACE: Cemiplimab Trial According to ctDNA Levels NCT06917573 | Fundación GECP | Phase 2 |
| Recruiting | Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NS NCT06167460 | Gene Solutions | — |
| Recruiting | Patient-centered, Optimal Integration of Survivorship and Palliative Care NCT04900935 | Massachusetts General Hospital | N/A |
| Recruiting | Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC NCT05681780 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Withdrawn | CISH Inactivated TILs in the Treatment of NSCLC NCT05566223 | Intima Bioscience, Inc. | Phase 1 / Phase 2 |
| Terminated | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancr NCT05631574 | Biomea Fusion Inc. | Phase 1 |
| Unknown | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma NCT05675033 | Fujian Cancer Hospital | Phase 2 |
| Unknown | SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC NCT05583409 | Li Zhang | N/A |
| Recruiting | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresecta NCT05361174 | Iovance Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Ruxolitinib for Cancer Cachexia NCT04906746 | Tu Dan | EARLY_Phase 1 |
| Unknown | Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Canc NCT05588206 | First People's Hospital of Hangzhou | Phase 1 / Phase 2 |
| Unknown | Randomized Controlled Clinical Study of Drug Therapy Combined With Thoracic Radiotherapy for Non-oligometastat NCT05176067 | Guizhou Medical University | N/A |
| Completed | Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer NCT06525246 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer NCT04670445 | Massachusetts General Hospital | N/A |
| Unknown | Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Fac NCT04142931 | Dr. Ronnie Shapira | Phase 1 |
| Recruiting | Study of Crizotinib for ROS1 and MET Activated Lung Cancer NCT04084717 | University Health Network, Toronto | Phase 2 |
| Active Not Recruiting | Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments NCT04056247 | OncoHost Ltd. | — |
| Unknown | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites NCT04267575 | Jerome Canady, M.D. | N/A |
| Completed | Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Ad NCT03911219 | iOMEDICO AG | — |
| Completed | BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Syste NCT03959137 | MSD Belgium BVBA | — |
| Terminated | KN046 in Patients With Advanced Non-small Cell Lung Cancer NCT03838848 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 |
| Active Not Recruiting | Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC NCT03611738 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Terminated | Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer NCT03559049 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC NCT03742687 | Danish Lung Cancer Group | N/A |
| Terminated | Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer NCT03087708 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Withdrawn | Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads NCT03023904 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Unknown | Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer. NCT03119519 | Southern Medical University, China | Phase 2 |
| Completed | Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-i NCT03305380 | Maastricht Radiation Oncology | — |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Withdrawn | Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer NCT03121417 | Emory University | Phase 2 |
| Recruiting | Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cance NCT03199651 | Ohio State University Comprehensive Cancer Center | N/A |
| Unknown | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That C NCT03048500 | Northwestern University | Phase 2 |
| Completed | Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer NCT02947386 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL) NCT03176173 | Stanford University | N/A |
| Completed | Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesi NCT02658097 | Case Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-sm NCT03137771 | NRG Oncology | Phase 2 |
| Completed | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 NCT03049618 | University of Southern California | Phase 2 |
| Terminated | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations NCT02949843 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell L NCT03595644 | Tongji Hospital | Phase 2 |
| Unknown | Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC NCT04530708 | Swedish Lung Cancer Study Group | N/A |
| Completed | TG4010 and Nivolumab in Patients With Lung Cancer NCT02823990 | Megan Daly, MD | Phase 2 |
| Withdrawn | A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Smal NCT02831491 | Eli Lilly and Company | Phase 2 |
| Completed | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors NCT02897375 | Emory University | Phase 1 |
| Completed | S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) NCT02728596 | SWOG Cancer Research Network | N/A |
| Completed | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases NCT02858869 | Emory University | Phase 1 |
| Completed | Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell L NCT02879994 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurre NCT02581943 | Wake Forest University Health Sciences | Phase 2 |
| Withdrawn | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery an NCT02567396 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer NCT02451865 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomog NCT02819024 | Barbara Ann Karmanos Cancer Institute | N/A |
| Terminated | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Pro NCT02650635 | Mayo Clinic | Phase 1 |
| Terminated | MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer NCT02400814 | Megan Daly, MD | Phase 1 |
| Completed | Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer NCT02655913 | Clifford Hospital, Guangzhou, China | Phase 1 / Phase 2 |
| Terminated | Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Remove NCT02566421 | Wake Forest University Health Sciences | N/A |
| Completed | Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib NCT02364609 | Jonathan Riess | Phase 1 |
| Completed | A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC NCT02451930 | Eli Lilly and Company | Phase 1 |
| Active Not Recruiting | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or NCT02495896 | University of Southern California | Phase 1 |
| Withdrawn | Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors NCT01971489 | Roswell Park Cancer Institute | Phase 1 |
| Completed | 18F-FSPG PET/CT for Cancer Patients on Therapy NCT02599194 | Andrei Iagaru | Phase 2 |
| Active Not Recruiting | S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recu NCT02438722 | SWOG Cancer Research Network | Phase 2 / Phase 3 |
| Completed | Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status NCT02426658 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cance NCT02132884 | Fox Chase Cancer Center | N/A |
| Completed | Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer NCT02009436 | Albert Einstein College of Medicine | Phase 1 |
| Completed | Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non NCT02243748 | City of Hope Medical Center | N/A |
| Completed | Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lun NCT02470468 | SOTIO a.s. | Phase 1 / Phase 2 |
| Withdrawn | Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy NCT02106559 | Ohio State University Comprehensive Cancer Center | N/A |
| Terminated | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung C NCT02134912 | SWOG Cancer Research Network | Phase 2 |
| Recruiting | Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung NCT02178163 | Barbara Ann Karmanos Cancer Institute | N/A |
| Completed | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Ca NCT02206334 | NRG Oncology | Phase 1 |
| Completed | Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV No NCT02245100 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | — |
| Terminated | Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surg NCT02134886 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer NCT02145078 | Barbara Ann Karmanos Cancer Institute | N/A |
| Withdrawn | Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient W NCT01928160 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Ce NCT01737502 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chem NCT02045446 | University of Texas Southwestern Medical Center | Phase 2 |
| Completed | Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small NCT01784640 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Ch NCT01948141 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients NCT01999881 | University of Wisconsin, Madison | N/A |
| Terminated | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection NCT01249443 | AIDS Malignancy Consortium | Phase 1 |
| Withdrawn | Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Canc NCT02017925 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers NCT01935336 | University of Colorado, Denver | Phase 2 |
| Completed | Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer NCT01839955 | Neelesh Sharma MD PhD | Phase 1 |
| Completed | PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell NCT01723800 | City of Hope Medical Center | Phase 1 |
| Completed | PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stag NCT02073968 | Albert Einstein College of Medicine | Phase 2 |
| Terminated | Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer NCT01935947 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung C NCT01781741 | Roswell Park Cancer Institute | EARLY_Phase 1 |
| Completed | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675 | Sanjiv Sam Gambhir | Phase 1 / Phase 2 |
| Completed | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced N NCT01620190 | University of Washington | Phase 2 |
| Completed | Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Thei NCT01729689 | Stanford University | N/A |
| Completed | Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cel NCT01664754 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Terminated | Circulating Tumor Cells in Lung Cancer NCT01658332 | Central Hospital, Nancy, France | N/A |
| Terminated | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Hea NCT01528137 | Stanford University | Phase 1 |
| Withdrawn | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer NCT01383668 | Mayo Clinic | Phase 1 |
| Terminated | First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer NCT01337154 | CytRx | Phase 2 |
| Withdrawn | Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body NCT01325753 | Wake Forest University Health Sciences | N/A |
| Terminated | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Ur NCT01282333 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NS NCT01310244 | Acrotech Biopharma Inc. | Phase 1 / Phase 2 |
| Terminated | RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment NCT01193868 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Canc NCT01193881 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Rec NCT00955305 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients NCT01026467 | Wake Forest University Health Sciences | — |
| Terminated | Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With NCT00976677 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lun NCT00986674 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NCT00963807 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung NCT00937482 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-s NCT00738881 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small NCT00778167 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy NCT00638937 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer NCT00602797 | University of Nebraska | Phase 2 |
| Completed | Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis NCT01014598 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung NCT00499655 | City of Hope Medical Center | Phase 2 |
| Completed | FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung C NCT00564733 | University of Washington | Phase 2 |
| Completed | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage NCT01557959 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung C NCT00481078 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer NCT00459342 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384 | National Cancer Institute (NCI) | Phase 1 |
| Completed | E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer NCT00400829 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB NCT00387374 | National Cancer Institute (NCI) | Phase 2 |
| Completed | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell L NCT00368992 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer NCT00387465 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer NCT00362882 | National Cancer Institute (NCI) | Phase 2 |
| Completed | IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer NCT00300586 | Hospices Civils de Lyon | Phase 3 |
| Completed | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurre NCT00950365 | Albert Einstein College of Medicine | Phase 2 |
| Completed | Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Ca NCT00408460 | University of Washington | Phase 2 |
| Completed | Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer NCT00247416 | Susanne Arnold | Phase 2 |
| Completed | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Sta NCT00118183 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer NCT00118144 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lu NCT00138203 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer NCT00098540 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors NCT00655655 | Mayo Clinic | Phase 1 |
| Completed | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer NCT00087412 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer NCT00085280 | National Cancer Institute (NCI) | N/A |
| Terminated | Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or NCT00088933 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer NCT00084981 | National Cancer Institute (NCI) | Phase 1 |
| Completed | STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With NCT00088088 | Synta Pharmaceuticals Corp. | Phase 1 / Phase 2 |
| Completed | CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer NCT00079235 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer NCT00062101 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer NCT00075751 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer NCT00088959 | National Cancer Institute (NCI) | Phase 1 |
| Completed | GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-S NCT00074022 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Can NCT00055757 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can NCT00068497 | National Cancer Institute (NCI) | N/A |
| Completed | Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refracto NCT00066768 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Tre NCT00228358 | University of Washington | Phase 1 |
| Completed | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carc NCT00063895 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lun NCT00052338 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurr NCT00021060 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Terminated | A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carbop NCT00042302 | QLT Inc. | Phase 3 |
| Terminated | A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as Fi NCT00042315 | QLT Inc. | Phase 3 |
| Terminated | Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer NCT00040768 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leuke NCT00039091 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer NCT00029003 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Car NCT01004731 | University of Alabama at Birmingham | Phase 1 / Phase 2 |
| Completed | Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Canc NCT00006929 | National Cancer Institute (NCI) | Phase 2 |
| Completed | FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Can NCT00020202 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER NCT00004883 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer NCT00003869 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer NCT00003497 | Burzynski Research Institute | Phase 2 |